FlowCardia, Inc. Appoints Deborah DeFilippo CFO - Gilde Healthcare

FlowCardia, Inc. Appoints Deborah DeFilippo CFO

June 18, 2008

SUNNYVALE, Calif., June 18, 2008 — FlowCardia, Inc., a medical device company developing endovascular devices for coronary and peripheral chronic total occlusion (CTO) recanalization, today announced the appointment of Deborah DeFilippo to the position of Chief Financial Officer. Ms. DeFilippo comes to FlowCardia with over 19 years of experience in Medical Devices. 

Most recently, Ms. DeFilippo served as Chief Financial Officer and Vice President, Business Development for the Guidant Cardiac Surgery business. Prior to that, she held a variety of executive positions at Guidant divisions as well as the Corporate Office of Guidant. Earlier, Ms. DeFilippo was the Director of Finance and Information Systems at Devices for Vascular Intervention prior to DVI’s acquisition by Guidant. Ms. DeFilippo holds a B.A. from Stanford University.

“We are tremendously pleased that Deborah will be joining FlowCardia. She is not only a very experienced financial executive but has also overseen such functions as Strategic Planning, Information Systems and Business Reengineering during her time with Guidant,”

said Wick Goodspeed, President and CEO of FlowCardia.

“Deborah will be a great addition to our management team and a substantial contributor to our sales growth and transition to profitability over the next few years.”

“I’m thrilled to be returning to the medical device field and joining FlowCardia at such an exciting time,”

said Ms. DeFilippo.

“FlowCardia is growing rapidly in its first year of commercialization and I am enthusiastic about the opportunity to help the Company become the leading CTO Device Company in the world.”

FlowCardia, Inc. is a privately held medical device company established in 2002 to design and manufacture endovascular CTO recanalization systems. Additional information is available on the Company’s Web Site at www.flowcardia.com.

CONTACT
Mark Page
Sr. Director Marketing
FlowCardia, Inc.
T: 408-617-0352 ext. 301

SOURCE
FlowCardia, Inc.

Gilde Healthcare company PureSpring announces FDA IND clearance for Phase 1/2 trial for primary IgA nephropathy (IgAN)

Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PS-002, enabling...
July 9, 2025

Gilde Healthcare’s private equity fund combines Artinis and NIRx into a world-leading neuroimaging group

Gilde Healthcare today announces the combined private equity investments in Artinis Medical Systems (Netherlands) and NIRx Medical Technologies (Germany/United States), both pioneers in functional Near-Infrared Spectroscopy (fNIRS) solutions. This dual transaction brings together two highly...
July 8, 2025

Gilde Healthcare company SpliceBio secures $135 Million financing to advance SB-007 in Stargardt disease and expand pipeline

Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as Gilde Healthcare and other existing investors  Proceeds will support clinical development of lead program SB-007...
June 11, 2025